Glaucoma News

A marketing authorization for Rhokiinsa, for the reduction of elevated IOP in open-angle glaucoma or ocular hypertension, has been approved by the European Commission, according to a press release.

Patients with glaucoma who underwent Baerveldt implantation by residents experienced similar outcomes and IOP reduction 1 year postoperatively when compared with implantations performed by glaucoma specialists, according to a study.

ELT Sight has acquired the IP and assets for MLase’s excimer ophthalmic laser system for glaucoma surgery, according to a press release.

Primary open-angle glaucoma may be associated with a genetic variation in individuals with African ancestry, a study found.

SAN FRANCISCO — At the American Academy of Ophthalmology meeting, Oliver Hvidt, CEO and co-founder of Norlase, discusses the company’s newest device, the Leaf laser photocoagulator.

A Japanese phase 2 clinical study of netarsudil ophthalmic solution showed a significant reduction in mean intraocular pressure compared with placebo, Aerie Pharmaceuticals announced in a press release.

On the court and in the field of play, the risk for sports-related eye injuries is prevalent. Knowing how to properly treat the injuries as well as wearing the proper gear may not only reduce the severity of the injury, but also may prevent eye injury.

The German state of Saxony has granted a $7.5 million grant to Mannin, a technology partner of Q BioMed Inc., to develop novel pharmaceuticals and biologic treatments for glaucoma, according to a press release.

Investigators found that selective laser trabeculoplasty was not superior to topical medication in maintaining quality of life outcomes when used as first-line therapy for glaucoma.

Few ocular adverse events occurred 5 years after micro-stent implantation in patients with open-angle glaucoma, with minimal evidence of corneal decompensation, according to findings published in the American Journal of Ophthalmology.